The EuroSIDA study: 25 years of scientific achievements

Laut, Kristina Grønborg; Kirk, Ole; Rockstroh, Jürgen K.; Phillips, Andrew; Ledergerber, Bruno; Gatell, José M.; Gazzard, Brian; Horban, Andrzéj; Karpov, Igor; Losso, Marcelo; Monforte, Antonella d’Arminio; Pedersen, Court; Ristola, Matti; Reiss, Peter; Scherrer, Alexandra U.; Wit, Stéphane De; Aho, Inka; Rasmussen, Line Dahlerup; Svedhem, Veronica; Wandeler, Gilles; Pradier, Christian; Chkhartishvili, Nikoloz; Matulionytė, Raimonda; Oprea, Cristiana; Kowalska, Justyna D.; Begovać, Josip; Miró, José M.; Guaraldi, Giovanni; Paredes, Roger; Raben, Dorthe; Podlekareva, Daria; Peters, Lars; Lundgren, Jens D; Mocroft, Amanda

doi:10.1111/hiv.12810

Cited by 23 publications

(37 citation statements)

References 52 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Logistic regression was used to calculate the odds of having a known response to DAAs, and factors associated with achieving SVR12. Factors adjusted for were age, gender, region of Europe (South/Argentina, Central West, North, Central East, East; regions are defined in [23]), ethnicity, HIV risk group (MSM, IDU, other), CD4 nadir and baseline CD4 cell count (both as continuous variable (per 100/mm 3 ) and categorised as ≤500 , >500 (cells/mm 3 ), and unknown), baseline HIV-RNA ( ≤500 , >500 copies per mL, unknown), HCV treatment regimen, stage of liver fibrosis, HCV genotype, HCV-RNA (positive and unquantified, <500,000, ≥500,000 IU/mL) ever received cART (defined as at least three antiretroviral drugs from at least two drug classes) at baseline, prior HCV treatment, baseline date…”

Section: Discussionmentioning

confidence: 99%

“…Where possible, participants continue to be followed if they transfer to another EuroSIDA clinic. Further details on the EuroSIDA cohort have been reported elsewhere [23], and can be found on the EuroSIDA website (https://www.chip.dk/Studies/EuroSIDA). This analysis included all individuals under follow-up in EuroSIDA that received interferon-free DAA therapy after 1 June 2014, as this is when EuroSIDA began collecting detailed information about HCV treatment including data on reasons for early discontinuation and treatment-limiting toxicities of HCV therapy.…”

Section: Eurosida Study Participantsmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study

Amele

Peters

Rodger

et al. 2021

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Objectives: To investigate the effectiveness, safety and reasons for premature discontinuation of directacting antivirals (DAAs) in a diverse population of HIV/HCV co-infected individuals in Europe.Methods: All HIV/HCV co-infected individuals in the EuroSIDA study that started interferon (IFN) free DAA treatment between 1/6/2014 and 1/3/2018 with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.Results: 1042 individuals started IFN-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, 789 (91.5%, 95% CI 89.7-93.4) of which achieved SVR12. There were no differences in SVR12 across regions of Europe (p=0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir +/-RBV (aOR 0.21 (95% CI 0.08-0.53) or ombitasvir/paritaprevir/dasabuvir +/-RBV (aOR 0.46 (95% CI 0.22-1.00) compared to sofosbuvir/ledipasvir +/-RBV. 43 (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly due to toxicity (n=14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n=15.3%) and was related to treatment with atazanavir and ribavirin.Conclusions: Our findings from real-world data on HIV/HCV co-infected individuals across Europe show DAA treatment is well tolerated, and that high rates of SVR12 can be achieved in all regions of Europe.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Eurosida Study Participantsmentioning

confidence: 99%

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study

Amele

Peters

Rodger

et al. 2021

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

“…EuroSIDA Cohort study (35 European countries plus Israel and Argentina) [30,31] The evolution in the prevalence of comorbidities and associated risk factors was also assessed in two cross-sectional analyses of the EuroSIDA cohort conducted in 2006 and 2014. EuroSIDA is a multinational, prospective cohort that includes HIV-positive populations from 35 European countries, as well as Argentina and Israel (open cohort).…”

Section: Athens Multicenter Aids Cohort Study (Amacs)mentioning

confidence: 99%

What do the changing patterns of comorbidity burden in people living with HIV mean for long‐term management? Perspectives from European HIV cohorts

et al. 2020

Self Cite

View full text Add to dashboard Cite

Undoubtedly, comorbidities complicate long‐term HIV management and have significant cost implications for healthcare systems. A better understanding of these comorbidities and underlying causes would allow for a more considered and proactive approach to the long‐term management of HIV. This review examines cross‐sectional analyses of six European cohort studies (Athens Multicenter AIDS Cohort Study, Aquitaine Cohort, EuroSIDA Cohort study, French claims EGB, German InGef Cohort and the Italian Cohort of Individuals, Naïve for Antiretrovirals), which included individuals with HIV followed over a certain period of time. Based on these cohorts, we examined how comorbidities have changed over time; how they compromise HIV management; and how much of a financial burden they impart. These data also provided a framework to explore the major issues of ageing and HIV and the practical implications of managing such issues in real‐life practice.

show abstract

“…The European Centre for Disease Prevention and Control (ECDC) publishes annual summaries of HIV across Europe, which may be more complete than data from individual cohorts, but are limited by a lack of information on outcomes after HIV-diagnosis and by incomplete reporting [15,18,19]. In contrast, large cohort studies, such as The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and Euro-SIDA, include participants with HIV from many cohorts and countries, and collect information on the prevalence and outcomes of LP [20,21]. Furthermore, the cohorts collect data from countries where surveillance data are limited.…”

Section: Introductionmentioning

confidence: 99%

Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016

Lacombe¹,

Groups²,

Cohere³

2020

BMC Infect Dis

View full text Add to dashboard Cite

Background Late presentation (LP), defined as a CD4 count < 350/mm3 or an AIDS-event at HIV-diagnosis, remains a significant problem across Europe. Linking cohort and surveillance data, we assessed the country-specific burden of LP during 2010–2016 and the occurrence of new AIDS events or deaths within 12 months of HIV-diagnosis believed to be attributable to LP. Methods Country-specific percentages of LP and AIDS-events/death rates (assessed with Poisson regression) observed in The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and EuroSIDA cohorts, were applied to new HIV-diagnoses reported to the European Centre for Disease Prevention and Control. The estimated number of LP in the whole population was then calculated, as was the number of excess AIDS-events/deaths in the first 12 months following HIV-diagnosis assumed to be attributable to LP (difference in estimated events between LP and non-LP). Results Thirty-nine thousand two hundred four persons were included from the COHERE and EuroSIDA cohorts, of whom 18,967 (48.4%; 95% Confidence Interval [CI] 47.9–48.9) were classified as LP, ranging from 36.9% in Estonia (95%CI 25.2–48.7) and Ukraine (95%CI 30.0–43.8) to 64.2% in Poland (95%CI 57.2–71.3). We estimated a total of > 320,000 LP and 12,050 new AIDS-events/deaths attributable to LP during 2010–2016, with the highest estimated numbers of LP and excess AIDS-events/deaths in Eastern Europe. Country-level estimates of excess events ranged from 17 AIDS-events/deaths (95%CI 0–533) in Denmark to 10,357 (95%CI 7768-147,448) in Russia. Conclusions Across countries in Europe, the burden of LP was high, with the highest estimated number of LP and excess AIDS-events/deaths being in Eastern Europe. Effective strategies are needed to reduce LP and the attributable morbidity and mortality that could be potentially avoided.

show abstract

The EuroSIDA study: 25 years of scientific achievements

Cited by 23 publications

References 52 publications

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study

What do the changing patterns of comorbidity burden in people living with HIV mean for long‐term management? Perspectives from European HIV cohorts

Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016

Contact Info

Product

Resources

About